MCID: ORL005
MIFTS: 46

Oral Candidiasis

Categories: Infectious diseases, Oral diseases

Aliases & Classifications for Oral Candidiasis

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 12 52 14 69
Thrush 12 3
Candidiasis of Mouth 12
Candidiasis, Oral 42
Oral Moniliasis 12
Equine Thrush 69
Thrush, Oral 12
Candidiasis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14262
ICD10 33 B37.0 B37.9
ICD9CM 35 112.0
MeSH 42 D002180
NCIt 47 C28137
UMLS 69 C0006849

Summaries for Oral Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives in the digestive tract and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to immunodeficiency 32b, monocyte and dendritic cell deficiency, autosomal recessive and median rhomboid glossitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Innate Immune System and Immune response IFN alpha/beta signaling pathway. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and kidney.

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

Wikipedia : 72 Oral candidiasis, also known as oral thrush among other names, is candidiasis that occurs in the mouth.... more...

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 immunodeficiency 32b, monocyte and dendritic cell deficiency, autosomal recessive 11.0
2 median rhomboid glossitis 10.9
3 reticular dysgenesis 10.9
4 candidiasis 10.8
5 bowman's membrane folds or rupture 10.6 DEFB1 DEFB4A
6 infundibulocystic basal cell carcinoma 10.6 DEFA1 DEFB4A
7 clear cell adenocarcinoma of ovary 10.6 DEFB1 DEFB4A
8 primary thrombocytopenia 10.5 DEFB4A LTF
9 gonadal disease 10.5 DEFB1 DEFB4A
10 optic atrophy 7 10.5 IL1A LTF
11 congenital insensitivity to pain with hyperhidrosis 10.4 CXCL8 LTF
12 bullous retinoschisis 10.4 CXCL8 DEFB4A
13 lymphangiectasia, intestinal 10.4 CXCL8 LTF
14 skin disease 10.4 CXCL8 DEFB4A
15 retinal vascular disease 10.4 CXCL8 LTF
16 lipoid nephrosis 10.4 DEFB4A IL1A
17 halal setton wang syndrome 10.4 CXCL8 LTF
18 lymph node palisaded myofibroblastoma 10.4 CXCL8 IL1A
19 urethra transitional cell carcinoma 10.3 DEFA1 IL1A
20 cantu sanchez-corona fragoso syndrome 10.3 HTN3 SKAP2
21 neuropathy 10.2 DEFB1 DEFB4A IL1A
22 senile reticular retinal degeneration 10.2 CXCL8 LTF
23 thymus clear cell carcinoma 10.2 CXCL8 DEFB4A
24 myofascial pain syndrome 10.2 CXCL8 IL1A
25 eosinophilic gastroenteritis 10.2 CXCL8 DEFB1 DEFB4A
26 granuloma inguinale 10.1 CXCL8 DEFB4A IL1A
27 palmoplantar keratosis 10.1 CXCL8 DEFB4A IL1A
28 leukoplakia 10.1
29 denture stomatitis 10.1 B2M SKAP2
30 tibial nerve palsy 10.1 B2M SKAP2
31 legionellosis 10.1 CXCL8 DEFB1 IL1A
32 autosomal recessive type iv ehlers-danlos syndrome 10.1 CXCL8 DEFB1 IL1A
33 chronic gonorrhea of cervix 10.0 DEFB4A HTN3 SKAP2
34 motor peripheral neuropathy 10.0 SKAP2 ST5
35 mucositis 10.0
36 spastic entropion 10.0 IL1A TMPO
37 oral hairy leukoplakia 10.0
38 idiopathic corneal edema 9.9 CXCL8 IL1A
39 leukemia 9.9
40 acquired immunodeficiency syndrome 9.9
41 primary biliary cirrhosis 9.9 B2M IL1A
42 acute erythroid leukemia 9.8 CXCL8 DEFB1 DEFB4A IL1A
43 mikulicz disease 9.8 IL1A LTF
44 inappropriate adh syndrome 9.8 CXCL8 DEFB1 DEFB4A IL1A
45 germ cell and embryonal cancer 9.8 CXCL8 DEFB4A IL1A LTF
46 hiv-1 9.8
47 acute leukemia 9.8
48 steatorrhea 9.7 B2M CXCL8
49 histiocytic and dendritic cell cancer 9.7 CXCL8 DEFB4A IL1A
50 stomatitis 9.7

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 37)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety Disorder
Bronchitis Bronchopneumonia
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophageal Candidiasis
Esophagitis Familial Atrial Fibrillation
Glossitis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Neutropenia Osteoporosis
Paralytic Ileus Peripheral Vascular Disease
Pharyngitis Pituitary Adenoma, Acth-Secreting
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:


oral manifestations

Drugs & Therapeutics for Oral Candidiasis

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Anidulafungin Approved, Investigational Phase 4,Phase 3 166663-25-8 166548
4
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2 137234-62-9 71616
5
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2 23593-75-1 2812
6
Terconazole Approved Phase 4 67915-31-5 441383
7
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11 Adrenergic Agents Phase 4,Phase 3,Phase 2
12 Adrenergic Agonists Phase 4,Phase 3,Phase 2
13 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
14 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
15 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
16 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
18 Autonomic Agents Phase 4,Phase 3,Phase 2
19 Bronchodilator Agents Phase 4,Phase 3,Phase 2
20 Dermatologic Agents Phase 4,Phase 3,Phase 2
21
Fluticasone Phase 4,Phase 3,Phase 2 90566-53-3, 80474-14-2 62924 22833648
22 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
23 glucocorticoids Phase 4,Phase 3
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
29 Respiratory System Agents Phase 4,Phase 3,Phase 2
30
Salmeterol xinafoate Phase 4,Phase 3 94749-08-3 56801
31 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
37 Antibiotics, Antitubercular Phase 4,Phase 3
38 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
39 Echinocandins Phase 4,Phase 3,Phase 2
40 Anti-Infective Agents, Local Phase 4,Phase 3
41 Hydroxyitraconazole Phase 4,Phase 3
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
43 Antitubercular Agents Phase 4,Phase 3
44
Posaconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 171228-49-2 147912
45
Gentian Violet Approved Phase 3 7438-46-2, 14426-25-6 3468
46
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
47
Nystatin Approved, Vet_approved Phase 3,Phase 2 1400-61-9 11953884
48
Pilocarpine Approved Phase 3 54-71-7, 92-13-7 5910
49
Procaterol Approved Phase 3 72332-33-3 688561
50
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 87)

id Name Status NCT ID Phase Drugs
1 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
3 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
4 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
5 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
6 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
7 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
8 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
9 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
10 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
11 Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole
12 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
13 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed NCT01427738 Phase 3 Gentian Violet;Nystatin oral suspension
14 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Completed NCT02818803 Phase 3 Miconazole
15 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
16 Effect of Probiotic Lozenge on Gingivitis and Periodontitis Completed NCT02203812 Phase 3 Probiotic Arm;Placebo Arm
17 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
18 Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Completed NCT02175771 Phase 3 Fp MDPI;FS MDPI;FLOVENT HFA;ADVAIR DISKUS;albuterol/salbutamol HFA
19 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed NCT01018186 Phase 3 Fluticasone Furoate/GW642444;Fluticasone propionate
20 Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Completed NCT00152867 Phase 3 Dexamethasone
21 Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy Completed NCT02181335 Phase 3 Respimat® Budesonide low dose;Respimat® Budesonide high dose;Turbohaler® Budesonide;Placebo
22 Prophylactic Antibiotics in Measles Completed NCT00168532 Phase 3 Sulfamethoxazole-Trimethoprim
23 Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole
24 Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3 micafungin;caspofungin
25 Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Completed NCT02184351 Phase 3 Roxanes's clotrimazole troches;Mycelex® troches
26 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Completed NCT00689338 Phase 3 Anidulafungin;Fluconazole;Voriconazole
27 A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems Completed NCT00002339 Phase 3 Fluconazole
28 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
29 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
30 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
31 A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. Completed NCT00163111 Phase 3 VFEND® I.V., Oral;Conventional amphotericin B;Diflucan IV, oral
32 Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis Completed NCT00659971 Phase 2 PAC113
33 A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole Completed NCT00001065 Phase 2 Amphotericin B
34 Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches Completed NCT00835029 Phase 2 Clotrimazole varnish;Clotrimazole troches
35 Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin Completed NCT02525458 Phase 2
36 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
37 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161 (oral);Fluconazole (oral)
38 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications Completed NCT01576718 Phase 2 Fp MDPI;Flovent Diskus;albuterol/salbutamol
39 Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure Completed NCT00168116 Phase 2
40 Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Completed NCT02244606 Phase 2 SCY-078;Fluconazole;Micafungin
41 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
42 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
43 A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients Completed NCT00002399 Phase 2 Posaconazole;Fluconazole
44 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection Completed NCT00739934 Phase 2 voriconazole (Vfend)
45 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
46 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 gel (3%);CD101 gel (1%);CD101 ointment (6%);CD101 ointment (1%);Fluconazole
47 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis Recruiting NCT02734862 Phase 2 CD101;Caspofungin;Fluconazole;intravenous placebo;oral placebo
48 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03253094 Phase 2 Fluconazole;SCY-078
49 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2 Amphotericin B
50 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Active, not recruiting NCT02267382 Phase 2 VT-1161;Placebo

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: candidiasis, oral

Genetic Tests for Oral Candidiasis

Anatomical Context for Oral Candidiasis

MalaCards organs/tissues related to Oral Candidiasis:

39
Skin, Tongue, Kidney, Colon, Salivary Gland, Neutrophil, T Cells

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 414)
id Title Authors Year
1
Assessment of Effectiveness of Fluconazole and Clotrimazole in Treating Oral Candidiasis Patients: A Comparative Study. ( 28462176 )
2017
2
Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. ( 28748027 )
2017
3
Quantity of Candida Colonies in Saliva: a8"A Diagnostic Evaluation for Oral Candidiasis. ( 28232964 )
2017
4
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
5
Development and Evaluation of Buccal Films Based on Chitosan for the Potential Treatment of Oral Candidiasis. ( 28108973 )
2017
6
Treatment and Prevention of Oral Candidiasis in Elderly Patients. ( 28566666 )
2017
7
Volatile organic compounds in the breath of oral candidiasis patients: a pilot study. ( 28601915 )
2017
8
A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. ( 28783552 )
2017
9
The potential management of oral candidiasis using anti-biofilm therapies. ( 28818264 )
2017
10
Topical Antimycotics for Oral Candidiasis in Warfarin Users. ( 27901310 )
2016
11
Adjuvant antifungal therapy using tissue tolerable plasma on oral mucosa and removable dentures in oral candidiasis patients: a randomised double-blinded split-mouth pilot study. ( 26932256 )
2016
12
Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. ( 27042008 )
2016
13
Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis. ( 27358561 )
2016
14
Oral candidiasis following steroid therapy for oral lichen planus. ( 26599999 )
2016
15
Elucidating the Role of Hyposalivation and Autoimmunity in Oral Candidiasis. ( 27998016 )
2016
16
Treatment of Oral Candidiasis Using PhotodithazineAr- Mediated Photodynamic Therapy In Vivo. ( 27253525 )
2016
17
Fluorescence of Candida in diagnosis of oral candidiasis. ( 28169259 )
2016
18
Oral candidiasis. ( 27343964 )
2016
19
Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern. ( 27403171 )
2016
20
FACTORS RELATED TO ORAL CANDIDIASIS IN ELDERLY USERS AND NON-USERS OF REMOVABLE DENTAL PROSTHESES. ( 27007560 )
2016
21
Plasma Levels of IFN-I^, IL-4, IL-6 and IL-17 in HIV-Positive Patients With Oral Candidiasis. ( 27127595 )
2016
22
Quantification of oral palatine Langerhans cells in HIV/AIDS associated oral Kaposi sarcoma with and without oral candidiasis. ( 27461637 )
2016
23
Prevention of Oral Candidiasis After Free Flap Surgery: Role of 3% Sodium Bicarbonate Saline in Oral Care. ( 27669373 )
2016
24
Molecular analysis of fungal populations in patients with oral candidiasis using next-generation sequencing. ( 27305838 )
2016
25
Development and evaluation of N-naphthyl-N,O-succinyl chitosan micelles containing clotrimazole for oral candidiasis treatment. ( 27050629 )
2016
26
Elimination of oral candidiasis may increase stimulated whole salivary flow rate. ( 27497081 )
2016
27
The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. ( 27977721 )
2016
28
Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis. ( 26719641 )
2015
29
Anti-Candida activity of aroma candy and its protective activity against murine oral candidiasis. ( 25855024 )
2015
30
The changing role of HIV-associated oral candidiasis in the era of HAART. ( 25868223 )
2015
31
Fabrication of a novel scaffold of clotrimazole-microemulsion-containing nanofibers using an electrospinning process for oral candidiasis applications. ( 25543979 )
2015
32
Local, systemic, demographic, and health-related factors influencing pathogenic yeast spectrum and antifungal drug administration frequency in oral candidiasis: a retrospective study. ( 26481235 )
2015
33
C/EBPI^ Promotes Immunity to Oral Candidiasis through Regulation of I^-Defensins. ( 26317211 )
2015
34
Direct Microscopy: A Useful Tool to Diagnose Oral Candidiasis in Children and Adolescents. ( 26329143 )
2015
35
Pseudomembranous Type of Oral Candidiasis is Associated with Decreased Salivary Flow Rate and Secretory Immunoglobulin A Levels. ( 25682023 )
2015
36
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. ( 26416861 )
2015
37
Innovation of natural essential oil-loaded Orabase for local treatment of oral candidiasis. ( 26170621 )
2015
38
Novel aggregation properties of Candida albicans secreted aspartyl proteinase Sap6 mediates virulence in oral candidiasis. ( 25870228 )
2015
39
Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease. ( 25422264 )
2015
40
Human immunodeficiency virus induced oral candidiasis. ( 26538978 )
2015
41
Evaluation of effect of topical ozone therapy on salivary Candidal carriage in oral candidiasis. ( 26096109 )
2015
42
Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis. ( 26596951 )
2015
43
Does scientific evidence for the use of natural products in the treatment of oral candidiasis exist? A systematic review. ( 25883668 )
2015
44
Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. ( 26456226 )
2015
45
Antifungal prescribing pattern and attitude towards the treatment of oral candidiasis among dentists in Jordan. ( 26148537 )
2015
46
Age-related alteration of expression and function of TLRs and NK activity in oral candidiasis. ( 25704085 )
2015
47
Fabrication of mucoadhesive chitosan coated polyvinylpyrrolidone/cyclodextrin/clotrimazole sandwich patches for oral candidiasis. ( 26256338 )
2015
48
Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. ( 25819801 )
2015
49
Fast-acting clotrimazole composited PVP/HPI^CD nanofibers for oral candidiasis application. ( 24554117 )
2014
50
Protection of mice from oral Candidiasis by heat-killed enterococcus faecalis, possibly through its direct binding to Candida albicans. ( 24682096 )
2014

Variations for Oral Candidiasis

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Pathways for Oral Candidiasis

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3
2
Show member pathways
11.64 CXCL8 IL1A IRF8
3
Show member pathways
11.39 DEFA1 DEFB1 DEFB4A HTN3 LTF
4 11.01 CXCL8 IL1A IRF8

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
2 Golgi lumen GO:0005796 9.33 DEFA1 DEFB1 DEFB4A
3 extracellular region GO:0005576 9.23 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.73 CXCL8 DEFA1 DEFB1 DEFB4A
2 immune response GO:0006955 9.7 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
3 defense response GO:0006952 9.67 CXCL8 DEFA1 DEFB1 DEFB4A
4 defense response to Gram-positive bacterium GO:0050830 9.65 DEFA1 DEFB1 DEFB4A
5 defense response to Gram-negative bacterium GO:0050829 9.63 DEFB1 DEFB4A LTF
6 antibacterial humoral response GO:0019731 9.58 DEFA1 DEFB1 LTF
7 iron ion homeostasis GO:0055072 9.56 B2M LTF
8 killing of cells of other organism GO:0031640 9.56 DEFA1 DEFB4A HTN3 LTF
9 retina homeostasis GO:0001895 9.55 B2M LTF
10 response to bacterium GO:0009617 9.54 DEFB1 IRF8
11 defense response to fungus GO:0050832 9.52 DEFA1 HTN3
12 innate immune response in mucosa GO:0002227 9.5 DEFA1 DEFB1 LTF
13 response to molecule of bacterial origin GO:0002237 9.49 B2M CXCL8
14 defense response to bacterium GO:0042742 9.43 DEFA1 DEFB1 DEFB4A HTN3 IRF8 LTF
15 defense response to protozoan GO:0042832 9.21 IRF8
16 antimicrobial humoral response GO:0019730 9.02 DEFA1 DEFB1 DEFB4A HTN3 LTF

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Oral Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....